Trial Profile
A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Subjects With Trigeminal Neuralgia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 15 Jun 2023
Price :
$35
*
At a glance
- Drugs Vixotrigine (Primary)
- Indications Trigeminal neuralgia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SURGE-1
- Sponsors Biogen
- 15 Jun 2023 This trial has been discontinued in Austria (Date of the global end of the trial: 15 Feb 2023).
- 18 May 2023 This trial has been discontinued in Belgium, Bulgaria, Slovakia and Finland (End Date: 25 Feb 2023), according to European Clinical Trials Database record.
- 06 May 2023 This trial has been Discontinued in Denmark, according to European Clinical Trials Database record.